Page last updated: 2024-11-04

suramin and Autism

suramin has been researched along with Autism in 4 studies

Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.

Research Excerpts

ExcerptRelevanceReference
"Suramin treatment did not affect VPA-induced upregulation of P2X4 and P2Y2 receptor expression in the hippocampus, and P2X4 receptor expression in the medial prefrontal cortex, but normalized an increased level of interleukin 6 (IL-6)."5.56Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism. ( Bambini-Junior, V; Bauer-Negrini, G; Brum Schwingel, G; Carello-Collar, G; Castillo, ARG; Corrêa-Velloso, J; Deckmann, I; Fontes-Dutra, M; Gonçalves, MCB; Gottfried, C; Hirsch, MM; Körbes-Rockenbach, M; Naaldijk, Y; Rabelo, B; Santos-Terra, J; Schneider, T; Staevie, GZ; Ulrich, H, 2020)
"Are the symptoms of autism caused by a treatable metabolic syndrome that traces to the abnormal persistence of a normal, alternative functional state of mitochondria? A small clinical trial published in 2017 suggests this is possible."2.58Antipurinergic therapy for autism-An in-depth review. ( Naviaux, RK, 2018)
"Suramin treatment did not affect VPA-induced upregulation of P2X4 and P2Y2 receptor expression in the hippocampus, and P2X4 receptor expression in the medial prefrontal cortex, but normalized an increased level of interleukin 6 (IL-6)."1.56Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism. ( Bambini-Junior, V; Bauer-Negrini, G; Brum Schwingel, G; Carello-Collar, G; Castillo, ARG; Corrêa-Velloso, J; Deckmann, I; Fontes-Dutra, M; Gonçalves, MCB; Gottfried, C; Hirsch, MM; Körbes-Rockenbach, M; Naaldijk, Y; Rabelo, B; Santos-Terra, J; Schneider, T; Staevie, GZ; Ulrich, H, 2020)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Hirsch, MM1
Deckmann, I1
Santos-Terra, J1
Staevie, GZ1
Fontes-Dutra, M1
Carello-Collar, G1
Körbes-Rockenbach, M1
Brum Schwingel, G1
Bauer-Negrini, G1
Rabelo, B1
Gonçalves, MCB1
Corrêa-Velloso, J1
Naaldijk, Y1
Castillo, ARG1
Schneider, T1
Bambini-Junior, V1
Ulrich, H1
Gottfried, C1
Naviaux, RK2
Zolkipli, Z1
Wang, L1
Nakayama, T1
Naviaux, JC1
Le, TP1
Schuchbauer, MA1
Rogac, M1
Tang, Q1
Dugan, LL1
Powell, SB1
Theoharides, TC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The UCSD Suramin Autism Treatment-1 (SAT1) Trial[NCT02508259]Phase 1/Phase 210 participants (Actual)Interventional2015-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Aberrant Behavior Checklist (ABC)

The full ABC is a 58-item parent rating with five factors: Irritability, Social Withdrawal, Stereotypy, Hyperactivity and Inappropriate Speech. Stereotypy is reported, and scores range from 0 to 21, with higher scores indicating worse behavior. A negative difference corresponds to decreased symptoms after treatment. A positive difference corresponds to increased symptoms after treatment. (NCT02508259)
Timeframe: 6 weeks compared to baseline

Interventionunits on a scale (Mean)
Suramin-4.0
Saline (Placebo)1.0

Autism Diagnostic Observation Schedule, 2nd Edition (ADOS2)

ADOS2 comparison scores are units on a scale of 0-10. A score of 7-10 was required for enrollment. A score of 7-10 is diagnostic for autism spectrum disorder (ASD). The higher the score, the more severe the core symptoms of autism spectrum disorder. Scores of 6 and below are considered off the ASD spectrum. (NCT02508259)
Timeframe: 6 weeks compared to baseline

Interventionunits on a scale (Mean)
Suramin-1.6
Saline (Placebo)-0.4

Autism Treatment Evaluation Checklist (ATEC)

The reported value is the Language sub-score of the ATEC, and the range for the language sub-score is 0-20. The higher the score, the worse the disability. Outcomes were measured at 6 weeks after treatment compared to baseline. A negative difference corresponds to a decrease in language disability, i.e an improvement in speech and language. A positive difference reflects an increase in language disability, i.e. a decrease in speech and language. (NCT02508259)
Timeframe: 6 weeks

Interventionunits on a scale (Mean)
Suramin-2.0
Saline (Placebo)-0.2

Expressive Language

Expressive One Word Picture Vocabulary Test (EOWPVT) scores are normalized for age. Typical language development produces a mean score of 100 with a standard deviation of 15. Outcomes for EOWPVT were expressed as the mean of the child-specific difference before and 6-weeks after treatment. For example, if the 6-week standard EOWPVT score was 59.6 and the baseline score was 63.8, the difference is -4.2 (= 59.6 - 63.8). A decrease in score at 6 weeks would corresponds to a decrease in language performance, while an increase, a positive difference, would reflect an increase. (NCT02508259)
Timeframe: 6 weeks compared to baseline

Interventionunits on a scale (Mean)
Suramin-4.2
Saline (Placebo)2.0

Repetitive Behavior Questionnaire

Total repetitive behavior was assessed using the Repetitive behavior questionnaire (RBQ), which has a scale from 0-87. Higher scores correspond to more severe repetitive behavior. Outcomes were analyzed as the difference in the score 6 weeks after treatment compared to baseline. A negative difference corresponds to improved behavior compared to baseline. A positive difference corresponds to worse behavior. (NCT02508259)
Timeframe: 6 weeks compared to baseline

Interventionunits on a scale (Mean)
Suramin-3.2
Saline (Placebo)-0.8

The Clinical Global Impression - Improvement Scale (CGI-I)

The CGI-I is scale that ranges from 1-7, reflecting the change in core autism behaviors after treatment. 1 is much improved, 4 is unchanged, and 7 is much worse. (NCT02508259)
Timeframe: Overall ASD symptoms at 6 weeks

Interventionunits on a scale (Mean)
Suramin-1.8
Saline (Placebo)0.0

Reviews

1 review available for suramin and Autism

ArticleYear
Antipurinergic therapy for autism-An in-depth review.
    Mitochondrion, 2018, Volume: 43

    Topics: Administration, Intravenous; Adolescent; Autistic Disorder; Child; Child, Preschool; Clinical Trials

2018

Other Studies

3 other studies available for suramin and Autism

ArticleYear
Effects of single-dose antipurinergic therapy on behavioral and molecular alterations in the valproic acid-induced animal model of autism.
    Neuropharmacology, 2020, 05-01, Volume: 167

    Topics: Animals; Anticonvulsants; Autistic Disorder; Brain; Disease Models, Animal; Female; Locomotion; Male

2020
Antipurinergic therapy corrects the autism-like features in the poly(IC) mouse model.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Animals; Autistic Disorder; Behavior, Animal; Brain; Calcium-Calmodulin-Dependent Protein Kinase Typ

2013
Extracellular mitochondrial ATP, suramin, and autism?
    Clinical therapeutics, 2013, Volume: 35, Issue:9

    Topics: Animals; Autistic Disorder; Female; Male; Suramin

2013